• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: KINETIC CONCEPTS, INC. ACTIV.A.C.¿ ION PROGRESS¿ REMOTE THERAPY MONITORING SYSTEM; OMP

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

KINETIC CONCEPTS, INC. ACTIV.A.C.¿ ION PROGRESS¿ REMOTE THERAPY MONITORING SYSTEM; OMP Back to Search Results
Model Number WNDARM
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Hematoma (1884); Hemorrhage/Bleeding (1888)
Event Date 02/26/2022
Event Type  Injury  
Event Description
On 28-feb-2022, the following information was provided to kci by the patient: the patient allegedly experienced a large hematoma and was admitted to the hospital.On 02-mar-2022, the following information was provided to kci by the case manager: the activ.A.C.¿ ion progress¿ remote therapy monitoring system reportedly "fell off" and the patient's wound began to bleed.Ems [emergency medical services] reportedly observed large clots and quikclot® was applied to cease the hemorrhage.The patient was admitted for a surgery consult and subsequently underwent a muscle flap procedure with repair of a graft.On 18-mar-2022, the following information was provided to kci by the case manager: on 26-feb-2022, the patient presented to the emergency department and was admitted to the hospital the same day.On 03-feb-2022, the device was tested per quality control procedure by the kci service center, and the device passed and met specification.On 10-feb-2022, the device was placed with the patient.On 15-mar-2022, the device was tested per quality control procedure by the kci service center and met specifications.Inspection and testing of the device did not reveal any evidence of an operational malfunction with the unit.
 
Manufacturer Narrative
Based on the information provided, it cannot be determined that the alleged hematoma/hemorrhage and surgery are related to the activ.A.C.¿ ion progress¿ remote therapy monitoring system.Multiple unsuccessful attempts were made to obtain additional clinical information.The patient was on anticoagulant treatment, and thus, was prone to bleeding.The patient also has significant vascular comorbidities which may have been a contributing factor in this event.The device passed quality control checks before and after patient placement.Device labeling, available in print and online, states: contraindications.Do not place foam dressings of the v.A.C.® therapy system directly in contact with exposed blood vessels, anastomotic sites, organs, or nerves.Warnings: bleeding: with or without using v.A.C.® therapy, certain patients are at high risk of bleeding complications.The following types of patients are at increased risk of bleeding, which, if uncontrolled, could be potentially fatal: patients who have weakened or friable blood vessels or organs in or around the wound as a result of, but not limited to: suturing of the blood vessel (native anastomosis or grafts) / organ.Infection.Trauma.Radiation.Patients without adequate wound hemostasis.Patients who have been administered anticoagulants or platelet aggregation inhibitors.Patients who do not have adequate tissue coverage over vascular structures.If v.A.C.® therapy is prescribed for patients who have an increased risk of bleeding complications, they should be treated and monitored in a care setting deemed appropriate by the treating physician.If active bleeding develops suddenly or in large amounts during v.A.C.® therapy, or if frank (bright red) blood is seen in the tubing or in the canister, immediately stop v.A.C.® therapy, leave dressing in place, take measures to stop the bleeding and seek immediate medical assistance.The v.A.C.® therapy units and dressings should not be used to prevent, minimize or stop vascular bleeding.Protect vessels and organs: all exposed or superficial vessels and organs in or around the wound must be completely covered and protected prior to the administration of v.A.C.® therapy.Always ensure that v.A.C.® foam dressings do not come in contact with vessels or organs.Use a thick layer of natural tissue should provide the most effective protection.If a thick layer of natural tissue is not available or is not surgically possible, multiple layers of non-adherent dressing material may be considered as an alternative, if deemed by the treating physician to provide a complete protective barrier.If using non-adherent materials, ensure they are secured in a manner that will maintain their protective position throughout therapy.Dressing changes wounds being treated with the v.A.C.® therapy system should be monitored on a regular basis.In a monitored, non-infected wound, v.A.C.® dressings should be changed every 48-72 hours, but no less than 3 times a week, with frequency adjusted by he clinician as appropriate.Infected wounds must be monitored often and very closely.For these wounds, dressings may need to be changed more often than 48-72 hours; the dressing changing intervals should be based on a continuing evaluation of the wound condition and the patient's clinical presentation, rather than a fixed schedule.Disclaimer: this information is submitted pursuant to 21 cfr 803, in compliance with the medical device reporting requirement and should not be considered to be an admission that a kinetic concepts, inc.Product malfunctioned, is defective or has caused serious injury.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ACTIV.A.C.¿ ION PROGRESS¿ REMOTE THERAPY MONITORING SYSTEM
Type of Device
OMP
Manufacturer (Section D)
KINETIC CONCEPTS, INC.
san antonio TX 78249
Manufacturer Contact
steven jackson
6203 farinon drive
san antonio, TX 78249
2102556438
MDR Report Key13863280
MDR Text Key293144547
Report Number3009897021-2022-00065
Device Sequence Number1
Product Code OMP
UDI-Device Identifier00849554005600
UDI-Public0100849554005600
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K201571
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Consumer,Health Professional
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 03/22/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/23/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberWNDARM
Device Catalogue Number416909
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer03/11/2022
Date Manufacturer Received02/28/2022
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured10/05/2020
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
Treatment
NEFEDIPINE (DOSAGE/FREQUENCY UNKNOWN); XARELTO (DOSAGE/FREQUENCY UNKNOWN)
Patient Outcome(s) Required Intervention; Hospitalization;
Patient Age90 YR
Patient SexFemale
Patient Weight52 KG
-
-